Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Environment

King Pharmaceuticals Fined For Air Pollution

by Glenn Hess
July 8, 2013 | A version of this story appeared in Volume 91, Issue 27

[+]Enlarge
Credit: vhasler
King Pharmaceuticals has its headquarters in Bristol, Tenn.
King Pharmaceuticals, Inc. headquarters in Bristol, Tennessee.
Credit: vhasler
King Pharmaceuticals has its headquarters in Bristol, Tenn.

King Pharmaceuticals has agreed to pay a $2.2 million fine and take steps to resolve allegations by federal prosecutors that emissions from the drug manufacturer’s Bristol, Tenn., plant violated the Clean Air Act. According to the complaint, King failed to adequately control emissions of methylene chloride and other hazardous air pollutants, violated the terms of its construction permit, and did not obtain the proper operating permit, as required under the Clean Air Act. The penalty should send a strong signal to the pharmaceutical industry that federal antipollution standards will be enforced, says Acting U.S. Assistant Attorney General Robert G. Dreher. On May 29, Baltimore-based UPM Pharmaceuticals announced it had purchased the 500,000-sq-ft Bristol plant from Pfizer, which acquired King in 2010 as a wholly owned subsidiary. Pfizer says the enforcement action began several years before the company bought King and “all underlying issues were corrected before or shortly after the acquisition.”

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.